23andMe was founded 19 years ago to provide saliva-based genetic testing of health and ancestry to consumers, going public in ...

The partner of former Theranos founder and chief executive Elizabeth Holmes, Billy Evans, has reportedly raised millions of ...

Early access programmes (EAPs) for novel medicines are an often-misunderstood strategy outside of western markets. In a new ...

The US has been at the centre of a shift in global trade dynamics these last few weeks, resulting from a rise in geopolitical ...

The revitalisation of GSK's blood cancer therapy Blenrep has continued with a second regulatory approval, in Japan, as a ...

BioMarin has been resetting its business with cuts in headcount and a narrowing of active programmes over the last year or so ...

The FDA has approved the first blood test for Alzheimer's disease based on a blood test – from Fujirebio – in a step forward ...

France's Sanofi is the latest European pharma group to promise a big capital investment programme on manufacturing and R&D in ...

What if we could reprogramme the TME itself? Cutting-edge research suggests that engineered mesenchymal stem cells (MSCs) ...

Health tech firm Datavant has reached an agreement to acquire Aetion, a specialist in real-world evidence (RWE), pooling ...

It seems Novo Nordisk is leaving no stone unturned as it builds a pipeline of drug candidates for obesity and cardiometabolic ...

Jørgensen has agreed to stay on while the search for a successor is carried out, and the chair of the Novo Nordisk Foundation ...